BIIB
Biogen Inc.
BIIB's fundamentals are mixed, but it looks expensive: trading at 108x earnings, about seven times its usual 15x. Its downside scenario is more than ten times its upside.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BIIB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
BIIB's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BIIB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $24.84 | -90% |
| Fair | 15x | $34.21 | -86% |
| Forward | 17x | $250 | — |
| Expensive | 25x | $57.60 | -77% |
| Current | 108x | $250 | — |
Historical ranges are pointers, not guarantees.
BIIB's PE is in its expensive range at 108x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BIIB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BIIB has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BIIB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $14.72 | +535% |
| Q3 2026 | $2.32 | -79% |
| Q2 2026 | $5.63 | -46% |
| Q1 2026 | $9.30 | -8.1% |
| Q4 2025 | $8.79 | -21% |
| Q3 2025 | $10.96 | -0.9% |
| Q2 2025 | $10.45 | +32% |
| Q1 2025 | $10.12 | +26% |
| Q4 2024 | $11.18 | +40% |
BIIB has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BIIB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | +11% |
| Q2 2026 | $2.7B | +3.4% |
| Q1 2026 | $2.5B | +1.9% |
| Q4 2025 | $2.3B | -7.1% |
| Q3 2025 | $2.5B | +2.8% |
| Q2 2025 | $2.6B | +7.3% |
| Q1 2025 | $2.4B | +6.1% |
| Q4 2024 | $2.5B | +2.9% |
BIIB's revenue is recovering but still below its 2020 peak: $2.8B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.3% | -22 points |
| Q2 2026 | 4.8% | -23 points |
| Q1 2026 | 15% | +2.4 points |
| Q4 2025 | -2.5% | -14 points |
| Q3 2025 | 22% | +3.7 points |
| Q2 2025 | 28% | -0.2 points |
| Q1 2025 | 13% | -7.5 points |
| Q4 2024 | 12% | -0.3 points |
BIIB has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BIIB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BIIB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $600.4M | -51% |
| Q2 2026 | $408M | +204% |
| Q1 2026 | $594.3M | +167% |
| Q4 2025 | $468M | -35% |
| Q3 2025 | $1.2B | +36% |
| Q2 2025 | $134.3M | -77% |
| Q1 2025 | $222.2M | -56% |
| Q4 2024 | $721.6M | +$774.3M |
BIIB still generates free cash flow, though less than at its 2019 peak: $2.1B over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BIIB on cash flow, with more consistent year-over-year improvement.
BIIB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -900K shares |
| 1 year | +0.5% | +700K shares |
| 3 years | +2.1% | +3M shares |
| 5 years | -0.5% | -800K shares |
| Available history | -17% | -30.4M shares |
BIIB has 148M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q4 2022 | — |
| Q3 2022 | $250M |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | $750M |
| Q2 2021 | $450M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BIIB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BIIB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.5x | High |
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.5x | Healthy |
BIIB's net debt is about 4.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BIIB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.0 | Overbought |
| Stochastic | 85.4 | Overbought |
BIIB's weekly RSI is 71 (overbought) and its Stochastic is 85 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BIIB PE vs Healthcare Sector
| Metric | BIIB | Sector median | Relative |
|---|---|---|---|
| PE | 108x | 26x | 318% above |
| PE % | 100 | 29 | 71 pts above |
BIIB is trading at 108x earnings, a 318% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BIIB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $238.6 | 5% above |
| 20 week MA | $222.1 | 13% above |
| 50 week MA | $200.5 | 25% above |
| 100 week MA | $170.0 | 47% above |
| 200 week MA | $205.0 | 22% above |
BIIB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BIIB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $300.1 | $248.9 | -17% |
| 2021 | $248.9 | $235.4 | -5.4% |
| 2022 | $235.4 | $279.2 | +19% |
| 2023 | $279.2 | $258.8 | -7.3% |
| 2024 | $258.8 | $151.3 | -42% |
| 2025 | $151.3 | $177.1 | +17% |
| 2026 YTD | $177.1 | $250.5 | +41% |
BIIB has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.